BTG3 and benign neoplasm: BTG3 expression was detectable in normal ovary tissue (78.6 %, 22/28), benign tumor (80.0 %, 12/15), borderline tumor (41.7 %, 10/24), carcinoma (51.0 %, 127/249), and metastatic carcinoma in omentum (50.0 %, 24/48), respectively.